title: [Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice].
abstract: BACKGROUND
  Recently, combination S-1 and CDDP chemotherapy is considered as a standard regimen for unresectable or recurrent gastric cancer. Second-line chemotherapy is reportedly important to improve survival, and combination of Irinotecan and Mitomycin C as second-line chemotherapy has proven effective in phase II study of JCOG 0109-DI.
  
  
  OBJECTIVE
  We assessed the efficacy of combination of Irinotecan and Mitomycin C as second-line chemotherapy for unresectable and recurrent gastric cancer.
  
  
  METHODS
  We treated 12 patients receiving combination of Irinotecan and Mitomycin C as second-line chemotherapy between Nov. 2002 and Apr. 2006.
  
  
  RESULTS
  The response rate was 42% including 2 complete response. Progression-free survival was 6.1 months, and time to progression was 5.4 months. Median survival time after the start of second-line chemotherapy was 11.2 months, and after first-line treatment 20.5 months. One-year survival rate was 50%, and 2-year survival rate was 33%.
  
  
  CONCLUSIONS
  In our hospital, combination of Irinotecan and Mitomycin C as second-line chemotherapy prolonged median survival time, and seemed to be an effective regimen.
authors.affiliation: Dept. of Gastroenterology, Kumamoto Regional Medical Center Hospital.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Miyamoto
authors.forename: Motoki
authors.initials: M
authors.lastname: Yoshida
authors.forename: Takenori
authors.initials: T
authors.lastname: Yamanouchi
authors.forename: Kikuo
authors.initials: K
authors.lastname: Kanda
authors.forename: Katsunori
authors.initials: K
authors.lastname: Zinnouchi
authors.forename: Takeaki
authors.initials: T
authors.lastname: Kiyozumi
authors.forename: Ikurou
authors.initials: I
authors.lastname: Koba
authors.forename: Ryukichi
authors.initials: R
authors.lastname: Akashi
authors.forename: Katsurou
authors.initials: K
authors.lastname: Sagara
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D016685:Mitomycin; D000077146:Irinotecan; D002166:Camptothecin